Outset Medical is thrilled to announce the successful raising of $169,000,000 in its latest funding round—a milestone that will power the next phase of growth for the company and its revolutionary technology. As a medical technology company pioneering a first-of-its-kind solution designed to reduce the cost and complexity of dialysis, Outset Medical continues to redefine the boundaries of patient care and clinical efficiency. At the heart of its innovation is the Tablo Hemodialysis System, an FDA-cleared platform that transforms the dialysis experience by enabling adaptable, user-friendly treatment from the hospital to the home. This breakthrough system streamlines the care process for medical providers and offers patients the opportunity to receive dialysis anytime, anywhere and by anyone, ensuring that high-quality care is not confined by traditional clinical settings.
The infusion of this capital will be strategically allocated to accelerate the development and broader deployment of Tablo, as well as to enhance its integrated features such as water purification, on-demand dialysate production, and innovative two-way wireless data transmission. By empowering a proprietary data analytics platform, Tablo is laying the groundwork for a holistic approach to dialysis that not only meets the demands of today’s treatment environment but also catalyzes future medical advancements. The funding also signals strong investor confidence in Outset Medical's vision to simplify and improve the dialysis continuum of care, ultimately striving to set new standards in medical technology and patient-centric healthcare delivery. With this new capital, Outset Medical is poised to extend its reach, impact more lives, and continue its journey of transforming the dialysis landscape.
